Lyumjev ® ▼ (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Lyumjev Summary of Product Characteristics (SmPC)

Lyumjev® ▼ (insulin lispro): Citrate and Effect as Excipient

Citrate is an excipient in Lyumjev formulation that acts to increase vascular permeability.

Lyumjev - Citrate in Formulation

Sodium citrate is an excipient that acts to increase vascular permeability, resulting in the accelerated absorption of insulin lispro.1-4

Citrate is a common GRAS ingredient used in many pharmaceutical formulations.5-7

References

1. Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro formulation containing citrate and treprostinil demonstrates faster absorption and onset of insulin action in healthy subjects [abstract]. Diabetes. 2017;66(suppl 1):A253. American Diabetes Association abstract 976‑P. http://dx.doi.org/10.2337/db17-890-1488

2. Michael MD, Zhang C, Siesky AM, et al. Exploration of the Mechanism of Accelerated Absorption for a Novel Insulin Lispro Formulation [abstract]. Diabetes. 2017;66(suppl 1):A250. http://dx.doi.org/10.2337/db17-890-1488

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Lyumjev [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

5. US Food and Drug Administration (FDA). Generally Recognized as Safe (GRAS). Updated September 6, 2019. Accessed July 3, 2020. https://www.fda.gov/food/ingredientspackaginglabeling/gras/

6. US Food and Drug Administration (FDA). Select Committee on GRAS Substances (SCOGS) Opinion: Citric acid, Citrates. Updated September 24, 2015. Accessed July 3, 2020. http://wayback.archive-it.org/7993/20171031063409/https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260861.htm

7. US Food and Drug Administration (FDA). CFR - Code of Federal Regulations Title 21. US Food and Drug Administration. Updated April 1, 2019. Accessed July 3, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1751

Glossary

GRAS = generally recognized as safe

URLi = ultra rapid lispro

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: August 06, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question